Isabelle Ragueneau-Majlessi

Summary

Affiliation: University of Washington
Country: USA

Publications

  1. pmc A useful tool for drug interaction evaluation: the University of Washington Metabolism and Transport Drug Interaction Database
    Houda Hachad
    Department of Pharmaceutics, University of Washington, H272 Health Sciences Center, Box 357610, Seattle, WA 98195, USA
    Hum Genomics 5:61-72. 2010
  2. ncbi request reprint Quantitative correlations among CYP3A sensitive substrates and inhibitors: literature analysis
    Isabelle Ragueneau-Majlessi
    Drug Interaction Database Unit, University of Washington, Department of Pharmaceutics, Seattle, WA 98195, USA
    Curr Drug Metab 8:810-4. 2007
  3. ncbi request reprint Carbamazepine pharmacokinetics are not affected by zonisamide: in vitro mechanistic study and in vivo clinical study in epileptic patients
    Isabelle Ragueneau-Majlessi
    Department of Pharmaceutics, University of Washington, H 272 Health Sciences Building, PO Box 357610, Seattle, WA 98195, USA
    Epilepsy Res 62:1-11. 2004
  4. ncbi request reprint Lack of pharmacokinetic interactions between steady-state zonisamide and valproic acid in patients with epilepsy
    Isabelle Ragueneau-Majlessi
    Department of Pharmaceutics, University of Washington, Seattle, Washington, USA
    Clin Pharmacokinet 44:517-23. 2005
  5. pmc Predicting substrates of the human breast cancer resistance protein using a support vector machine method
    Eszter Hazai
    Virtua Drug Ltd, Csalogány Street 4, Budapest H 1015, Hungary
    BMC Bioinformatics 14:130. 2013
  6. ncbi request reprint Lack of clinically significant pharmacokinetic interactions between zonisamide and lamotrigine at steady state in patients with epilepsy
    Rene H Levy
    Department of Pharmaceutics, University of Washington, H 272 Health Sciences Building, Box 357610, Seattle, Washington 98195, USA
    Ther Drug Monit 27:193-8. 2005
  7. ncbi request reprint Lack of a clinically significant effect of zonisamide on phenytoin steady-state pharmacokinetics in patients with epilepsy
    Rene H Levy
    Department of Pharmaceutics, University of Washington, Seattle, Washington 98195, USA
    J Clin Pharmacol 44:1230-4. 2004
  8. pmc e-PKGene: a knowledge-based research tool for analysing the impact of genetics on drug exposure
    Houda Hachad
    Department of Pharmaceutics, University of Washington, Seattle, USA
    Hum Genomics 5:506-15. 2011
  9. ncbi request reprint New antiepileptic drugs: review on drug interactions
    Houda Hachad
    Department of Pharmaceutics, University of Washington, Seattle, Washington 98195, USA
    Ther Drug Monit 24:91-103. 2002
  10. ncbi request reprint Levetiracetam does not alter the pharmacokinetics of an oral contraceptive in healthy women
    Isabelle Ragueneau-Majlessi
    Department of Pharmaceutics, University of Washington, Seattle 98195, USA
    Epilepsia 43:697-702. 2002

Collaborators

Detail Information

Publications13

  1. pmc A useful tool for drug interaction evaluation: the University of Washington Metabolism and Transport Drug Interaction Database
    Houda Hachad
    Department of Pharmaceutics, University of Washington, H272 Health Sciences Center, Box 357610, Seattle, WA 98195, USA
    Hum Genomics 5:61-72. 2010
    ..This review provides a brief description of the database organisation, its search functionalities and examples of use...
  2. ncbi request reprint Quantitative correlations among CYP3A sensitive substrates and inhibitors: literature analysis
    Isabelle Ragueneau-Majlessi
    Drug Interaction Database Unit, University of Washington, Department of Pharmaceutics, Seattle, WA 98195, USA
    Curr Drug Metab 8:810-4. 2007
    ..The average potencies of these inhibitors relative to ketoconazole were 27% for erythromycin, 17% for fluconazole and 19% for verapamil...
  3. ncbi request reprint Carbamazepine pharmacokinetics are not affected by zonisamide: in vitro mechanistic study and in vivo clinical study in epileptic patients
    Isabelle Ragueneau-Majlessi
    Department of Pharmaceutics, University of Washington, H 272 Health Sciences Building, PO Box 357610, Seattle, WA 98195, USA
    Epilepsy Res 62:1-11. 2004
    ..Based on the lack of clinically relevant in vitro and in vivo effects, adjustment of carbamazepine dosing should not be required with concomitant zonisamide administration...
  4. ncbi request reprint Lack of pharmacokinetic interactions between steady-state zonisamide and valproic acid in patients with epilepsy
    Isabelle Ragueneau-Majlessi
    Department of Pharmaceutics, University of Washington, Seattle, Washington, USA
    Clin Pharmacokinet 44:517-23. 2005
    ..A second aim was to characterise zonisamide pharmacokinetics in the presence of valproic acid...
  5. pmc Predicting substrates of the human breast cancer resistance protein using a support vector machine method
    Eszter Hazai
    Virtua Drug Ltd, Csalogány Street 4, Budapest H 1015, Hungary
    BMC Bioinformatics 14:130. 2013
    ..The final SVM model was integrated to a free web server...
  6. ncbi request reprint Lack of clinically significant pharmacokinetic interactions between zonisamide and lamotrigine at steady state in patients with epilepsy
    Rene H Levy
    Department of Pharmaceutics, University of Washington, H 272 Health Sciences Building, Box 357610, Seattle, Washington 98195, USA
    Ther Drug Monit 27:193-8. 2005
    ....
  7. ncbi request reprint Lack of a clinically significant effect of zonisamide on phenytoin steady-state pharmacokinetics in patients with epilepsy
    Rene H Levy
    Department of Pharmaceutics, University of Washington, Seattle, Washington 98195, USA
    J Clin Pharmacol 44:1230-4. 2004
    ..The pharmacokinetic measures of zonisamide in the presence of phenytoin were consistent with previous reports of induction of zonisamide metabolism by phenytoin...
  8. pmc e-PKGene: a knowledge-based research tool for analysing the impact of genetics on drug exposure
    Houda Hachad
    Department of Pharmaceutics, University of Washington, Seattle, USA
    Hum Genomics 5:506-15. 2011
    ..This review gives a brief description of the database organisation, its search functionalities and examples of use...
  9. ncbi request reprint New antiepileptic drugs: review on drug interactions
    Houda Hachad
    Department of Pharmaceutics, University of Washington, Seattle, Washington 98195, USA
    Ther Drug Monit 24:91-103. 2002
    ..Lamotrigine is eliminated mostly by glucuronidation and is susceptible to inhibition by valproic acid and induction by classic AEDs such as phenytoin, carbamazepine, phenobarbital and primidone...
  10. ncbi request reprint Levetiracetam does not alter the pharmacokinetics of an oral contraceptive in healthy women
    Isabelle Ragueneau-Majlessi
    Department of Pharmaceutics, University of Washington, Seattle 98195, USA
    Epilepsia 43:697-702. 2002
    ..This study was designed to evaluate whether levetiracetam, a novel antiepileptic drug (AED), influences the pharmacokinetics of steroid oral contraceptives...
  11. pmc Importance of multi-p450 inhibition in drug-drug interactions: evaluation of incidence, inhibition magnitude, and prediction from in vitro data
    Nina Isoherranen
    Department of Pharmaceutics, School of Pharmacy, University of Washington, Box 357610, Seattle, WA 98195, USA
    Chem Res Toxicol 25:2285-300. 2012
    ..The results of this study suggest that inhibition of multiple clearance pathways in vivo is clinically relevant, and the risk of DDIs with object drugs may be best evaluated in studies using multi-P450 inhibitors...
  12. doi request reprint Pharmacokinetics, safety, and tolerability of the new antiepileptic carisbamate in the elderly
    Rene Levy
    Department of Pharmaceutics, University of Washington, H 272, Health Science Building, Box 357610, Seattle, WA 98195 7610, USA
    Epilepsy Res 79:22-30. 2008
    ..To evaluate the effect of age on the disposition of two different oral formulations of carisbamate (RWJ-333369), a novel neuromodulator under investigation...
  13. ncbi request reprint Interaction between clopidogrel and proton pump inhibitors: hypothesis to explain multifactorial CYP2C19 inhibition
    Huixia Zhang
    Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, WA 98195, USA
    Drug Metab Lett 3:287-9. 2009
    ..A hypothesis is proposed to interpret the phenomenon of PPI inhibition based in part on the finding that clopidogrel is itself an inhibitor of CYP2C19...